HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; HG153 a Menin-MLL tablet; HG248; and HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation; HGP1069, a ROCK2 inhibitor eye drop. Further, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Additionally, the company focus on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. HitGen Inc. was founded in 2012 and is based in Chengdu, China.
Metrics to compare | 688222 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688222PeersSector | |
---|---|---|---|---|
P/E Ratio | 138.0x | 38.7x | −0.5x | |
PEG Ratio | 14.26 | 0.64 | 0.00 | |
Price/Book | 6.4x | 3.5x | 2.6x | |
Price / LTM Sales | 21.3x | 6.0x | 3.3x | |
Upside (Analyst Target) | −25.0% | 5.1% | 43.4% | |
Fair Value Upside | Unlock | 10.1% | 7.1% | Unlock |